Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients

Background: Erythropoiesis-stimulating agents including epoetin alfa have been a mainstay of anemia management in patients with chronic kidney disease. Although the standard practice has been to administer epoetin alfa to patients on hemodialysis (HD) intravenously (IV), subcutaneous (SQ) epoetin al...

Full description

Bibliographic Details
Main Authors:	Bhanu Prasad, Maryam Jafari, Julie Toppings, Linda Gross, Joanne Kappel, Flora Au
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-06-01
Series:	Canadian Journal of Kidney Health and Disease
Online Access:	https://doi.org/10.1177/2054358120927532

Similar Items

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
by: Steven Fishbane, et al.
Published: (2019-09-01)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
by: Arrieta J, et al.
Published: (2014-10-01)

Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients
by: Amel Harzallah, et al.
Published: (2015-01-01)

INFLUENCE OF EPOETIN ALFA ON LEVEL OF PROINFLAMMATORY AND ANTIINFLAMMATORY CYTOKINE OF PATIENTS IN MAINTENCE HEMODIALYSIS
by: I. Dudar, et al.
Published: (2014-03-01)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
by: E.J.F. Santos, et al.
Published: (2018-05-01)

Darbepoetin versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
by: Pilar M Samper Ots, et al.
Published: (2008-01-01)

Epoetin Alfa: A Cause of Coronary Artery Thrombosis
by: Muhammad Umer Siddiqui, et al.
Published: (2017-01-01)

A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment
by: J Wilson, et al.
Published: (2007-04-01)

The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data
by: Shukla Rakesh, et al.
Published: (2009-02-01)

Effect of Epoetin Alfa and Sodium Valproate in Patients with Myelodysplastic Syndrome
by: Seyed Ashkan Hosseini, et al.
Published: (2020-06-01)

Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial
by: Andrea L. Woodland, et al.
Published: (2017-06-01)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
by: Jay B. Wish, et al.
Published: (2019-09-01)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
by: Shimamatsu K
Published: (2014-12-01)

Epoetin beta for the treatment of chemotherapy-induced anemia: an update
by: Galli L, et al.
Published: (2015-03-01)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
by: November McGarvey, et al.

Epoetin alfa ja namaluva nefrotoksicnosta inducirana so cisplatin kaj staorci
by: Dimce Zafirov, et al.
Published: (2006-06-01)

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report
by: Behler Caroline M, et al.
Published: (2009-07-01)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017-10-01)

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
by: Kurtz JE, et al.
Published: (2016-10-01)

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
by: Iain RJ Macpherson, et al.
Published: (2009-03-01)

Own experience of treatment by epoetin-α (Eralfon®) of chemotherapy induced anemia
by: S A Bolshakova, et al.
Published: (2017-01-01)

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
by: Ohashi N, et al.
Published: (2012-03-01)

The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients
by: Maoujoud O, et al.
Published: (2016-02-01)

Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
by: Gilbertson David T, et al.
Published: (2013-02-01)

Cost-effectiveness analysis of darbepoetin after switch from epoetin-beta in patients on hemodialysis: an Italian single-center retrospective study
by: Mario Eandi, et al.
Published: (2006-03-01)

Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis
by: Paulo D. Picon, et al.
Published: (2014-08-01)

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
by: Giovanni Rosti, et al.
Published: (2017-01-01)

Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hypeferritinemia
by: Shahrbanoo Keyhanian, et al.
Published: (2008-01-01)

The effect of intravenous ascorbic acid in hemodialysis patients with normoferritinemic anemia
by: Dae Woong Kang, et al.
Published: (2012-03-01)

A Multicenter assessment of the on-label and off-label usage of erythropoietic agents( epoetin alfa and darbepoetin alfa) in critically ill ICU patients : A retrospective study
by: Lee, Seina Park
Published: (2006)

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
by: Davis-Ajami ML, et al.
Published: (2014-04-01)

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease
by: Ken Aizawa, et al.
Published: (2018-01-01)

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach
by: Ly Minh Nguyen, et al.
Published: (2020-10-01)

Évaluation pharmacodynamique et sécurité d'emploi de l'Époétine alfa chez les patients aux soins intensifs
by: Darveau, Martin
Published: (2016)

Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients
by: Satirapoj B, et al.
Published: (2017-09-01)

Clinical impact of epoetins in the treatment of anemia with special emphasis on patients with lymphoid malignancies. : dosing, iron supplementation and safety
by: Hedenus, Michael
Published: (2007)

Higher‐risk myelodysplastic syndrome in an elderly patient: Long‐term partial remission with low‐dose prednisone, G‐CSF, and epoetin alfa
by: Anwarul Islam
Published: (2021-09-01)

Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
by: Natasha Irrera, et al.
Published: (2015-01-01)

Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
by: Robert D. M. Hadden, et al.
Published: (2015-01-01)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
by: Jean Darloy, et al.
Published: (2019-01-01)

Cannot write session to /tmp/vufind_sessions/sess_5bu0tf9250g9949gdfi1d6utq3